Publications by authors named "David E Allison"

Claim this Profile
P
Population pharmacokinetics of bevacizumab in cancer patients with external validation.
Kelong Han, Thomas Peyret, Mathilde Marchand, Angelica Quartino, Nathalie H Gosselin, David E Allison

Cancer Chemother Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.
Kelong Han, Thomas Peyret, Angelica Quartino, Nathalie H Gosselin, Sridharan Gururangan, David E Allison

Br J Clin Pharmacol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Kelong Han, Jin Jin, Mauricio Maia, John Lowe, Martina A Sersch, David E Allison

AAPS J· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.
Jing Li, Manish Gupta, Denise Jin, Yan Xin, Jennifer Visich, David E Allison

Cancer Chemother Pharmacol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A guide to rational dosing of monoclonal antibodies.
Shuang Bai, Karin Jorga, Yan Xin, Denise Jin, Yanan Zheng, David E Allison

Clin Pharmacokinet· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.
Leslie A Khawli, Sirj Goswami, Ryan Hutchinson, Zephania W Kwong, Jihong Yang, David E Allison

MAbs· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
David B Agus, Christopher J Sweeney, Michael J Morris, David S Mendelson, Douglas G McNeel, David E Allison

J Clin Oncol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Michael S Gordon, Daniela Matei, Carol Aghajanian, Ursula A Matulonis, Molly Brewer, David E Allison

J Clin Oncol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.
Camellia W Adams, David E Allison, Kelly Flagella, Leonard Presta, Janet Clarke

Cancer Immunol Immunother· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
David B Agus, Michael S Gordon, Charles Taylor, Ronald B Natale, Beth Karlan, David E Allison

J Clin Oncol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers.
David E Allison, Steven G Gourlay, Eugene Koren, Robert M Miller, Judith A Fox

BioDrugs· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis